secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001558370-23-000173
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharmaceuticals receives Nasdaq approval to transfer listing to Capital Market
--------------------------------------------------------------------------------

- Transfer from Nasdaq Global Select to Capital Market approved, effective Jan 11, 2023.
- Company met minimum stockholders' equity requirement (Rule 5550(b)(1)) and market value of publicly held shares (Rule 5550(a)(5)).
- Common stock continues trading under ticker KALA on the Nasdaq Capital Market.
- Listing transfer does not affect corporate governance requirements or continuous trading nature.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023000173/0001558370-23-000173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023000173/kala-20230109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer